Results 91 to 100 of about 1,866 (169)

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies

RMD Open
Objective To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3 studies and ...
H. Marzo-Ortega, V. Navarro-Compán, Maureen Dubreuil, P. Mease, M. Magrey, M. Rudwaleit, M. D'Agostino, K. Gaffney, Jonathan Kay, C. de la Loge, U. Massow, V. Taieb, T. Vaux, A. Deodhar   +13 more
semanticscholar   +1 more source

Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Raj Chovatiya, Afsaneh Alavi, Takuya Miyagawa, Irina Turchin, Thrasyvoulos Tzellos, Hessel H. van der Zee, Christina Crater, Bartosz Lukowski, Nicola Tilt, Christos C. Zouboulis   +9 more
wiley   +1 more source

Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan

Dermatology and Therapy
Introduction Psoriasis is a chronic, inflammatory skin disease that significantly impairs patients’ quality of life (QOL). Several biologics with varying mechanisms of action are approved for treating moderate-to-severe plaque psoriasis (PSO) in Japan ...
Atsuyuki Igarashi, Koichi Shiraishi, Shota Saito, Tomoya Kudo, Yukihiko Iizuka, Eiko Yamamura, Masakazu Hase   +6 more
doaj   +1 more source

Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy

International Journal of Dermatology
Bimekizumab, a monoclonal antibody targeting interleukin (IL)‐17A and IL‐17F, has shown efficacy in psoriatic arthritis (PsA) clinical trials, but real‐world data on its effectiveness are limited. This study aimed to evaluate its real‐world effectiveness
G. Caldarola, A. Dattola, N. Bernardini, Veronica Blundo, E. Campione, E. De Luca, Domenico Giordano, A. Giunta, G. Moretta, D. Orsini, G. Pagnanelli, A. Richetta, Andrea Picchianti Diamanti   +12 more
semanticscholar   +1 more source

Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis [PDF]

, 2023
OBJECTIVES: To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of interleukin‑17F and 17A, with biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in non-radiographic axial ...
Willems, Damon, Taieb, Vanessa, Orme, Michelle, Pritchett, David, Machado, Pedro M, Deodhar, Atul, Gensler, Lianne S, Mørup, Michael   +7 more
core  

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriatic arthritis (
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes   +7 more
doaj   +1 more source

Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study.

Actas Dermo-Sifiliográficas
BACKGROUND Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European Medicines Agency (EMA) for the treatment of hidradenitis
M. Mansilla-Polo, M. Pons-Benavent, P. Fernández-Crehuet, E. Vilarrasa, C. Albanell-Fernández, E. Morales-Tedone, F. Rausell-Félix, R. Alcalá-García, M. Matellanes-Palacios, G. Martin-Ezquerra, F. Alfageme, C. Ciudad-Blanco, M. T. López-Villaescusa, J. M. Segura-Palacios, J. C. Pascual-Ramírez, M. Fernández-Díaz, D. Falkenhain-López, M. García-Gil, A. Agusti-Mejias, N. No-Pérez, N. Naranjo-Guerrero, Á. Estenaga-Pérez, R. García-Ruíz, L. Mahiques-Santos, P. Garbayo-Salmons, A. Martorell, B. Escutia-Muñoz, D. Martín-Torregrosa, C. Cuenca-Barrales, C. Ureña Paniego, R. Botella-Estrada, A. Molina-Leyva   +31 more
semanticscholar   +1 more source

Bimekizumab for the treatment of hidradenitis suppurativa

Immunotherapy
Hidradenitis suppurativa (HS) is a painful, inflammatory dermatosis involving recurrent abscesses, nodules and tunnels in intertriginous regions. Biologics and other immunomodulators have significantly expanded the treatment options available for HS. Bimekizumab is a monoclonal antibody targeting both interleukin-17A and interleukin-17F, key mediators ...
Rayad B Shams, Christopher J Sayed
openaire   +2 more sources

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review

Bimekizumab is the most recent interleukin-17 inhibitor (IL-17i) to receive approval for adult plaque psoriasis; unlike other IL-17i agents, it exclusively targets IL-17A/IL-17F.
Sood, S (via Mendeley Data), Sood, Siddhartha   +1 more
core   +1 more source

Sycosis Barbae Treated With Bimekizumab

Australasian Journal of Dermatology
ABSTRACT Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31‐year‐old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)‐17A and IL‐17F.
Matiar Madanchi, Riccardo Curatolo, Lorenzo S. Pelloni, Hazem A. Juratli   +3 more
openaire   +2 more sources